Caris Life Sciences, established in 2008, is a precision oncology company that integrates molecular science with artificial intelligence. The firm develops tools for cancer diagnostics, including comprehensive tumor profiling and blood-based tests. Its technical focus spans next-generation sequencing, bioinformatics, and AI-driven analytics.
The company's portfolio includes several key products. MI Profile is a molecular profiling service for cancer patients, and MI Cancer Seek is a blood-based diagnostic solution. Caris ChromoSeq is noted as the world's first combined Whole Genome Sequencing and Whole Transcriptome sequencing solution.
Operating within the healthcare, diagnostics, and biotechnology sectors, Caris Life Sciences employs a team of scientific and medical professionals. The company states it is driven by innovation, compassion, and purpose in its work.
